Jasper is a biotechnology company focused on enabling safer conditioning agents that expand the application of curative hematopoietic stem cell transplants and gene therapies. The company's lead compound, JSP191, is in clinical development as a conditioning antibody that clears hematopoietic stem cells from bone marrow in patients undergoing a stem cell transplant.
Jasper Therapeutics total Funding
Jasper Therapeutics latest funding size
Time since last funding
|a year ago|
Jasper Therapeutics investors
|Roche Venture Fund, Abingworth, Alexandria Venture Investments, Quiming Venture Partners USA, Supervisor Capital|
Jasper Therapeutics has 33 Twitter Followers. The number of followers has increased 18.9% month over month and increased 32.8% quarter over quarter
Tweets last 30 days
Avg. likes per Tweet
Tweets with engagement
Who are Jasper Therapeutics key executives?
Jasper Therapeutics's key executives are Bill Lis, Mitchell Mutz and Jeet Mahal.
Who are Jasper Therapeutics competitors?
Competitors of Jasper Therapeutics include Transgene, ProtoKinetix and Cord Blood America.
Receive alerts for 300+ data fields across thousands of companies